Skip to main content
SpringerLink
Log in

Newer Antiepileptic Drugs in Status Epilepticus: Prescription Trends and Outcomes in Comparison with Traditional Agents

  • Original Research Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Introduction

Newer antiepileptic drugs (AEDs) are increasingly prescribed; however, relatively limited data are available regarding their use in status epilepticus (SE) and the impact on outcome.

Objectives

The aim of this study was to explore the evolution in prescription patterns of newer and traditional AEDs in this clinical setting, and their association with prognosis.

Methods

We analyzed our prospective adult SE registry over a 10-year period (2007–2016) and assessed the yearly use of newer and traditional AEDs and their association with mortality, return to baseline conditions at discharge, and SE refractoriness, defined as treatment resistance to two AEDs, including benzodiazepines.

Results

In 884 SE episodes, corresponding to 719 patients, the prescription of at least one newer AED increased from 0.38 per SE episode in 2007 to 1.24 per SE episode in 2016 (mostly due to the introduction of levetiracetam and lacosamide). Traditional AEDs (excluding benzodiazepines) decreased over time from 0.74 in 2007 to 0.41 in 2016, correlating with the decreasing use of phenytoin. The prescription of newer AEDs was independently associated with a lower chance of return to baseline conditions at discharge (odds ratio [OR] 0.58, 95% confidence interval [CI] 0.40–0.84) and a higher rate of SE refractoriness (OR 19.84, 95% CI 12.76–30.84), but not with changes in mortality (OR 1.08, 95% CI 0.58–2.00).

Conclusion

We observed a growing trend in the prescription of newer AEDs in SE over the last decade; however, our findings might suggest an associated increased risk of SE refractoriness and new disability at hospital discharge. Pending prospective, comparative studies, this may justify some caution in the routine use of newer AEDs in SE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Claassen J, Riviello JJ, Silbergleit R. Emergency neurological life support: status epilepticus. Neurocrit Care. 2015;23(Suppl 2):S136–42.

    Article  PubMed  Google Scholar 

  2. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.

    Article  PubMed  Google Scholar 

  3. Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.

    Article  CAS  PubMed  Google Scholar 

  4. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.

    Article  CAS  PubMed  Google Scholar 

  6. de Groot MCH, Schuerch M, de Vries F, Hesse U, Oliva B, Gil M, et al. Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison. Epilepsia. 2014;55(5):666–73.

    Article  PubMed  Google Scholar 

  7. Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95(1–2):51–9.

    Article  PubMed  Google Scholar 

  8. Berman E, Marom E, Ekstein D, Blatt I, Eyal S. Utilization of antiepileptic drugs in Israel. Epilepsy Behav. 2016;61:82–5.

    Article  PubMed  Google Scholar 

  9. Italiano D, Capuano A, Alibrandi A, Ferrara R, Cannata A, Trifirò G, et al. Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005–2011. Br J Clin Pharmacol. 2015;79(6):1010–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000–2005. Eur J Neurol. 2007;14(12):1317–21.

    Article  CAS  PubMed  Google Scholar 

  11. Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia. 2010;51(10):2207–10.

    Article  CAS  PubMed  Google Scholar 

  12. Madžar D, Kuramatsu JB, Gerner ST, Huttner HB. Assessing the value of topiramate in refractory status epilepticus. Seizure. 2016;38:7–10.

    Article  PubMed  Google Scholar 

  13. Santamarina E, Toledo M, Sueiras M, Raspall M, Ailouti N, Lainez E, et al. Usefulness of intravenous lacosamide in status epilepticus. J Neurol. 2013;260(12):3122–8.

    Article  CAS  PubMed  Google Scholar 

  14. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137–41.

    Article  CAS  PubMed  Google Scholar 

  15. Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2008;79(5):588–9.

    Article  CAS  PubMed  Google Scholar 

  16. Rüegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav. 2008;12(3):477–80.

    Article  PubMed  Google Scholar 

  17. Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959–63.

    Article  CAS  PubMed  Google Scholar 

  18. Alvarez V, Januel J-M, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52(7):1292–6.

    Article  CAS  PubMed  Google Scholar 

  19. Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav. 2016;64 (Part A):110–5.

  20. Jaques L, Rossetti AO. Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis. Epilepsy Behav. 2012;24(1):70–3.

    Article  PubMed  Google Scholar 

  21. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251–6.

    Article  PubMed  Google Scholar 

  22. Marchi NA, Novy J, Faouzi M, Stähli C, Burnand B, Rossetti AO. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43(5):1003–9.

    Article  PubMed  Google Scholar 

  23. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120–2.

    Article  CAS  PubMed  Google Scholar 

  24. Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry. 2006;77(5):611–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol. 2008;255(10):1561–6.

    Article  PubMed  Google Scholar 

  26. Redecker J, Wittstock M, Benecke R, Rösche J. Comparison of the effectiveness of four antiepileptic drugs in the treatment of status epilepticus according to four different efficacy criteria. Epilepsy Behav. 2015;49:351–3.

    Article  PubMed  Google Scholar 

  27. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Vazquez B. Monotherapy in epilepsy: role of the newer antiepileptic drugs. Arch Neurol. 2004;61(9):1361–5.

    Article  PubMed  Google Scholar 

  30. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology. 2003;60(11 Suppl 4):S2–12.

    Article  CAS  PubMed  Google Scholar 

  31. Ney JP, van der Goes DN, Nuwer MR, Nelson L, Eccher MA. Continuous and routine EEG in intensive care: utilization and outcomes, United States 2005–2009. Neurology. 2013;81(23):2002–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Betjemann JP, Josephson SA, Lowenstein DH, Burke JF. Trends in status epilepticus-related hospitalizations and mortality: redefined in US practice over time. JAMA Neurol. 2015;72(6):650–5.

    Article  PubMed  Google Scholar 

  33. Navarro V, Dagron C, Elie C, Lamhaut L, Demeret S, Urien S, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  34. Alvarez V, Lee JW, Drislane FW, Westover MB, Novy J, Dworetzky BA, et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison. Epilepsia. 2015;56(8):1275–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol. 2001;133(6):867–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Nicolas J-M, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–9.

    Article  CAS  PubMed  Google Scholar 

  37. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999;34(2–3):161–8.

    Article  CAS  PubMed  Google Scholar 

  38. Wang X, Patsalos PN. A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin. Seizure. 2003;12(6):330–6.

    Article  CAS  PubMed  Google Scholar 

  39. Rossetti AO, Alvarez V, Januel J-M, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260(2):421–8.

    Article  PubMed  Google Scholar 

  40. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, et al. The Established Status Epilepticus Trial 2013. Epilepsia. 2013;54(Suppl 6):89–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Christine Stähli, RN, and the EEG technologists and fellows for help in data acquisition.

Author information

Authors and Affiliations

  1. Service de Neurologie, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois (CHUV), CHUV-BH07, and Lausanne University Hospital, 1011, Lausanne, Switzerland

    Isabelle Beuchat, Jan Novy & Andrea O. Rossetti

Authors
  1. Isabelle Beuchat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Novy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea O. Rossetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea O. Rossetti.

Ethics declarations

Funding

None.

Conflict of interest

Isabelle Beuchat, Jan Novy and Andrea Rossetti declare no conflicts of interest with regard to the findings reported in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beuchat, I., Novy, J. & Rossetti, A.O. Newer Antiepileptic Drugs in Status Epilepticus: Prescription Trends and Outcomes in Comparison with Traditional Agents. CNS Drugs 31, 327–334 (2017). https://doi.org/10.1007/s40263-017-0424-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-017-0424-1

Keywords

Search

Navigation